DongKook Life Science
Financials
Valuation Metrics
DongKook Life Science's Market Cap is ₩779B. At end of 2025 it was ₩1171B. Ranked #1393 of 2,436 in KR market (top 57%), #782 of 1,649 on KOSDAQ (top 47%), #155 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 66%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 77.88B KRW | KR#1,393/2,436 Sec#155/234 |
| Revenue | 128.38B KRW | KR#1,251/2,436 Sec#75/234 |
| Net Income | 8.71B KRW | KR#947/2,436 Sec#63/234 |
| Total Assets | 223.83B KRW | KR#1,209/2,436 Sec#87/234 |
| Net Assets | 133.64B KRW | KR#1,182/2,436 Sec#92/234 |
| Employees | 211 | KR#1,054/2,436 Sec#88/234 |
| Value | ||
| P/E | 8.94x | KR#646/2,436 Sec#31/234 |
| P/B | 0.58x | KR#979/2,436 Sec#47/234 |
| PEG | 3.58x | KR#826/2,436 Sec#56/234 |
| P/S | 0.61x | KR#1,077/2,436 Sec#50/234 |
| EV/EBITDA | 8.39x | KR#497/2,436 Sec#22/234 |
| FCF Yield | -6.75% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 6.52% | KR#842/2,436 Sec#63/234 |
| ROA | 3.89% | KR#810/2,436 Sec#71/234 |
| Op. Margin | 10.42% | KR#467/2,436 Sec#44/234 |
| Revenue Growth | -5.61% | KR#1,721/2,436 Sec#160/234 |
| Earnings Growth | 2.50% | KR#883/2,436 Sec#59/234 |
| Financial Health | ||
| Debt Ratio | 167.49% | KR#1,409/2,436 Sec#162/234 |
| Total Debt | 39.27B KRW | KR#1,081/2,436 Sec#78/234 |
| FCF | -5.26B KRW | KR#1,512/2,436 Sec#118/234 |
| Cash | 4.88B KRW | KR#2,003/2,436 Sec#183/234 |
| Current Ratio | 1.71x | KR#1,141/2,436 Sec#124/234 |
| Net Debt/EBITDA | 2.57x | KR#927/2,436 Sec#68/234 |
| Performance | ||
| 1Y Return | -52.49% | KR#2,097/2,436 Sec#196/234 |
| 1M Return | -0.61% | KR#796/2,436 Sec#64/234 |
| From 52W High | -54.32% | KR#1,355/2,436 Sec#115/234 |
| 1Y MDD | -55.53% | KR#1,186/2,436 Sec#94/234 |
| Trading | ||
| Volume | 40,620 shares | KR#1,692/2,436 Sec#156/234 |
| Foreign Own. | 3.45% | KR#958/2,436 Sec#93/234 |
| Per Share | ||
| EPS | 272 KRW | KR#1,123/2,436 Sec#77/234 |
| BPS | 4,178 KRW | KR#1,585/2,436 Sec#122/234 |
Company Info
Dongguk Pharmaceutical Life Science, established in 2017 and listed on KOSDAQ in 2025, manufactures and sells contrast agents, and distributes medical devices and diagnostic equipment. As a specialized contrast agent company, it launched Korea's first First generic contrast agent, Pamiray, and has 17 partners in 25 countries. Leveraging its radiology expertise and sales network from its contrast agent business, the company is expanding its AI medical device business and providing Total Patient Care. It is headquartered in Gangnam-gu, Seoul.